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The relaxin family of peptides consists of seven structurally related peptides, 
with a wide variety of biological functions, ranging from involvement in reproductive 
processes to functions as neuroendocrine modulators. 
Because of the complex, two-chained structure of the relaxins, and their lack 
of specificity for the various relaxin family receptors (RXFPs), design of simpler, 
more selective analogues is important for further investigation of their biological 
functions and as potential drug leads. 
The aim of this project was to introduce a helical structure around the 
receptor-binding region of single-chain relaxin analogues. This was approached by 
utilising helix capping sequences on truncated relaxin B-chains and by grafting of 
residues important for binding onto a stable peptide scaffold. 
Helix capping enhanced the helical properties compared to previous single-
chain analogues, but was unable to introduce a sufficiently stable helix. Despite the 
increased helical tendencies, no high-affinity analogues were found. As a result, the 
importance of Arg8 was investigated, and we have demonstrated that this residue 
might be more involved in binding than previously thought. 
We successfully synthesised a relaxin-3/chlorotoxin analogue, which appeared 
to fold correctly. However, the yield following oxidation was poor, and no bioactivity 
data or structural data confirming the correct fold was obtained within the time limits 
of the project. 
A secondary aim was to probe for favourable mutations around the receptor-
binding region by synthesising a combinational library. We were able to successfully 
synthesise a library of peptides with mutations in one position by inserting a mixture 
of amino acids at this coupling step in the solid phase peptide synthesis (SPPS) 
procedure. Although no significant improvement in binding was seen for the 
analogues generated, important methodological advances were made that will be used 
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1D   one-dimensional 
2D   two-dimensional 
3D   three-dimensional 
Boc   tert-butoxycarbonyl 
Buffer A  0.05 % trifluoracetic acid in water 
Buffer B  90% acetonitrile, 10% water, 0.05% trifluoracetic acid 
Buffer A/B  50/50 mixture of buffers A and B 
DIPEA  N,N-Diisopropylethylamine 
DMF   N,N-Dimethylformamide 
cAMP   Cyclic adenosine monophosphate 
CHO   Chinese hamster ovary 
CPRG   Chlorophenol red-!-D-galatopyranoside 
CRE   cAMP response element 
DODT   3,6-dioxa-1,8-octanedithiol 
ES-MS  Electrospray mass spectrometry 
Fmoc   9H-fluoren-9-ylmethyloxycarbonyl 
GPCR   G protein-coupled receptor 
HBTU  O-benzotriazol-1-yl-1,1,3,3-tetramethyluronium 
hexafluorophosphate 
HEK   Human embryonic kidney 
HPLC   High performance liquid chromatography 
ICV   Intracerebroventricular  
IGF   Insulin-like growth factor 
INSL   Insulin-like peptide 
iPVN   Intraparaventricular  
LDL-a   Low-density lipoprotein class A  
LGR   Leucine-rich repeat-containing G protein-coupled receptor 
LRR   Leucine-rich repeat  
MALDI-TOF-MS Matrix-assisted laser desorption/ionization time of flight mass 
spectrometry 
MS   Mass spectrometry 
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MRNA  Messenger ribonucleic acid  
NI   Nucleus incertus  
NMR   Nucleic magnetic resonance 
NOE   Nuclear Overhauser effect 
NOESY  Nuclar Overhauser effect spectroscopy 
RP-HPLC  Reverse phase high performance liquid chromatography 
RXFP   Relaxin family peptide receptor 
SPPS   Solid phase peptide synthesis 
TFA   Trifluoracetic acid 
TOCSY  Total correlation spectroscopy  
TIPS   Tri-isopropylsilane 
UV   Ultraviolet 


































1.1. Bioactive peptides 
 
Peptides are defined as compounds composed of two or more amino acids, 
coupled together by amide bonds. Peptides generally comprise of combinations of the 
20 different gene encoded amino acids. There are exceptions however, with peptides 
being post-translationally modified. 
A bioactive peptide is a peptide that shows some sort of biological activity. 
Bioactive peptides can be found in all parts of the natural world, and have a range of 
different functions. One function well known in humans, is the role peptides play as 
hormones. The most famous of the peptide hormones might be insulin, and its 
regulation of blood glucose levels. 
In other organisms peptides with more exotic functions are found; for instance 
peptides with antimicrobial properties, or peptide toxins produced to aid in defence, 
or in capture of prey. Worth mentioning here is cyclosporine, a peptide metabolite 
from the soil fungus Trichoderma polysporum, which is now widely used as an 
immunosuppressant drug. 
Peptides have many properties making them attractive drug leads; high 
activity and specific binding to their target, and generally low non-specific binding to 
molecules other than the target. Toxicity is also generally low, as is accumulation in 
tissue [1, 2]. However, peptides also have some major drawbacks as pharmaceuticals, 
including poor stability and unfavourable properties such as low oral availability and 
rapid clearance from the body, as well as a potential immunogenicity [1-3]. Because 
of these problems, much work is focused on improving peptide stability and 
developing delivery systems for peptide drugs [2, 3]. 
 




The family of relaxin peptide hormones consists of seven different peptides; 
relaxin 1-3 and insulin like peptide (INSL) 3-6. These peptides are structurally related 
to insulin and insulin-like growth factors (IGF) I and II, and together these ten 
peptides are referred to as the insulin/relaxin superfamily [4, 5]. One common 
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denominator for the relaxin peptides is their two-chained structure, where an A and a 
B chain are held together through cross-bracing by two interchain disulfide bonds, 
and one disulfide bond within the A-chain [4] (Figure 1). 
 
Figure 1. Sequence alignment of the peptides that make up the relaxin family. The concerved 
cysteine residues are highlighted in yellow, and their connectivity indicated by brackets. The 
overall fold of the family is expamplified by the crystal structure of relaxin-2, shown with the A-
chain in blue, and the B-chain in red. Disulfide bonds are shown in yellow. 
 
These disulfide bonds stabilise the overall structure, which is conserved in all 
of the relaxins. In the common structure, the A-chain folds into two helical segments, 
separated by a central !-strand. The helices are positioned anti-parallel to each other 
in a U-shaped structure. The B-chain consists of one central helix positioned across 
the U of the A-chain and a second !-strand forming an inter-chain !-sheet [6-9]. 
The focus of this project was to design new analogues of relaxin-2, relaxin-3 
and INSL5, and the rest of the introduction will focus on these members of the relaxin 
family.  
 
1.2.2. Biological roles and clinical applications 
 
Relaxin-2 was discovered in 1926, and the first observed biological role was 
in relaxing the pubic ligaments in pregnant guinea pigs, hence the name “relaxin” 
[10]. The sequence of porcine relaxin was first characterized in the 1970’s [4, 11, 12]. 
From originally being viewed as a reproductive hormone, its functional roles 
have later been expanded to include regulating the cardiovascular and renal systems, 
inhibiting collagen biosynthesis and promoting collagen breakdown, as well as 
regulating allergic responses [5, 13, 14]. 
Relaxin-2 is involved in the cardiovascular adaptations that occur during 
pregnancy, including increased plasma volume, cardiac output and heart rate. It has 
also been found to reduce blood pressure and vascular resistance [4, 13, 14]. Studies 
on pregnant rats have also shown glomerular filtration rate and effective renal plasma 
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flow to be proportional to plasma levels of relaxin [13]. Because of these effects on 
cardiovascular and renal systems, relaxin-2 has a potential therapeutic use in 
congestive heart failure. Relaxin-2 has passed phase II clinical trials for treatment of 
acute heart failure with promising results [15], and entered phase III trials on this 
indication. 
The use of relaxin-2 in women with severe preeclampsia is also being 
investigated in the clinic [16]. The pathophysiology of preeclampsia involves severe 
vasoconstriction, resulting in reduced blood flow to the placenta, hypertension, renal 
dysfunction and multiple organ failure [16]. Relaxin-2 is thought to improve this 
condition by increasing blood flow to the placenta, in addition to improving systemic 
heamodynamics and renal function in a way similar to the rationale for treatment of 
heart failure [16].  
Relaxin-2’s effects on connective tissue include inhibition of collagen 
synthesis and promotion of collagen breakdown in both reproductive and non-
reproductive tissues. This effect suggests a potential use as an anti-fibrotic agent [4, 5, 
13, 14]. 
Relaxin-2 induces cervical ripening in rats and pigs, and clinical trials on 
cervical ripening have been conducted on women with post-date pregnancies. In 
different trials relaxin-2 was administered intravaginally and intravenously, but 
neither trial showed any evidence of cervical ripening [4, 5]. 
Since the 1980’s over 500 human subjects have been treated with relaxin-2 in 
clinical trials on different indications, and relaxin-2 has shown an excellent safety 
profile [14]. 
INSL5 was first reported in 1999, and is expressed in the colon and uterus in 
humans [17]. In mice it has been found to be expressed in the enteroendocrine-like 
cells in the crypts in colonic epithelial layer [4, 18]. Its biological function is still 
being investigated. Work on INSL5 knock-out mice has suggested that INSL5 may 
play a role in regulation of fat and glucose metabolism [4, 19]. 
 Relaxin-3 is the latest addition to the relaxin family, discovered in 2002 [20]. 
Relaxin-3 is primarily expressed in the brain, but is also found in the spleen, thymus 
and testis [4, 20, 21]. 
In the brain, the main area where relaxin-3 is found is the nucleus incertus (NI) 
in the brainstem [20-22]. This area is close to other regions involved in behaviour 
control and regulation of stress responses [23, 24]. Relaxin-3 neurons also project 
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from the NI to other areas in the forebrain where relaxin family peptide receptor 
(RXFP) 3-positive neurons are present. These areas are involved in processes such as 
circadian rhythms, arousal and attention, learning and memory, stress responses and 
associated cognitive processes [23, 24]. In forced swim tests on rats, relaxin-3 
neuronal activity and relaxin-3 mRNA transcription has been shown to increase in 
response to stress [22]. These findings suggest that relaxin-3 is involved in regulation 
of stress responses. 
Relaxin-3 might also be involved in appetite regulation [25-27] and in long-
term control of food intake [27]. Acute injections of relaxin-3 
intracerebroventricularly (ICV) or intraparaventricularly (i-PVN) increase food intake 
and feeding behaviour in rats [25]. Chronic ICV or i-PVN administration of relaxin-3 
has been shown to increase cumulative food intake [26, 27], leading to increased body 
weight in rats [26]. 
Because of the wide range of physiological roles, relaxin-3 is under 
investigation as a drug lead for a variety of disease states. The observation that an 
RXFP3 agonist is able to block fear-associated “freezing” in rats (unpublished 
observation), in addition to the role relaxin-3 plays in stress regulation, suggests a 
potential in treatment of anxiety disorders such as phobias or post traumatic stress 
disorder. 
An RXFP3 antagonist has been reported to inhibit spatial memory in rats when 
injected into the medial septum [28], suggesting that relaxin-3 has a role in cognition. 
RXFP3 agonists may be relevant in treatment of dementia or other diseases associated 
with impaired cognition. 
The effect on food intake and appetite, and the role in stress regulation, gives 
RXFP3 receptor modulators potential as drug leads in treatment of mood-related 
metabolic disorders, such as anorexia. RXFP3 antagonists might also be leads for 
anti-obesity drugs [26]. 
 It was recently reported that relaxin-3 has antifibrotic properties similar to 
those of relaxin-2. These properties are mediated via relaxin-3’s action on RXFP1. It 






1.2.3.  Receptors  
 
Whereas insulin and IGFs bind to tyrosine kinase receptors, the structurally 
similar relaxins bind to G protein-coupled receptors (GPCR). Four GPCRs have been 
identified to date as relaxin receptors; RXFP 1-4 [21, 30-34]. 
The RXFP3 and 4 are classic peptide ligand GPCRs [4, 34] whereas the 
receptors RXFP1 and 2 belong to a subgroup of family A GPCRs termed leucine-rich 
repeat-containing G protein-coupled receptors (LGR) [4, 35]. These receptors are 
characterised by a large extracellular N-terminal leucine-rich repeat (LRR) domain. 
More specifically, RXFP1 and 2 belong to class C in the LGR subfamily [4, 35]. The 
extracellular domain of RXFP1 and 2 contains a low-density lipoprotein class A 
(LDL-a) at their N-termini, in addition to ten LRRs [4, 35]. The B-chain of the relaxin 
family peptides interacts with sites in the LRR domain, while features of the A-chain 




Figure 2. The RXFP receptors and their ligands. Cognate ligand-receptor pairs indicated by bold 
arrows, and additional interactions by fine arrows. Dotted lines denote a weak interaction, and 
red line an antagonistic interaction. 
 
RXFP3 is the endogenous receptor for relaxin-3 [21], but relaxin-3 also has 
high affinity to, and the ability to activate, RXFP1 and RXFP4 [32, 33]. Relaxin-3 
also activates RXFP2 to a lesser extent [8]. Relaxin-3 is thus able to bind to and 
activate receptors in both of the different subgroups of RXFP-receptors, and is the 
only relaxin peptide able to do so [4, 13] (Figure 2). 
INSL5 binds to, and activates, RXFP4 as its endogenous receptor [34], but is 
also able to weakly antagonise RXFP3 [4, 7, 34]. Relaxin-2 primarily binds and 
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activates RXFP1, but also has high affinity for RXFP2 [30]. INSL3 is only known to 
bind to its endogenous receptor [4, 31, 37].  
The native receptors for INSL4 and INSL6 have to date not been found [4], 
and little is known about their biological significance. 
 
1.2.4. Structure/activity relationship 
 
In 1992 the importance of the arginines B13 and B17 for relaxin-2’s biological 
activity was reported by Büllesbach and Schwabe [38]. Later, the binding site was 
expanded to include isoleucine B20 [39]. The triangular contact region Arg-xxx-Arg-
xx-Ile sequence is often referred to as the Relaxin binding motif or casette, or the 
RXXXRXXI cassette (Figure 3A). This sequence is essential for binding to relaxin-
2’s endogenous receptor RXFP1 [38, 39]. 
Relaxin-2 is also dependent on the A-chain to be able to activate the receptors 
RXFP1 and 2 [36, 40]. As previously mentioned, the primary binding occurs on the 
B-chain, involving the residues Arg13, Arg17 and Ile20 [40], but the A chain residues 
Thr16, Lys17 and Phe23 play a cooperative part in binding together with the B-chain 
binding region [40-42]. In addition, TrpB28 is involved in primary binding to RXFP2, 
but not to RXFP1 [40, 43].  
 
 
Figure 3. Crystal strucure of relaxin-2 (A.) and NMR solution structure of relaxin-3 (B.) A.) 
Residues in the relaxin-binding casette which are essential for binding to RXFP1 are labeled and 
side-chains shown in red. B.) Residues important for binding to RXFP3 are labeled, and side-
chains shown in blue. 
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Relaxin-3 also contains a relaxin-binding cassette exposed on the B-chain 
helix, and these residues together with some additional neighbouring residues were 
suggested to be involved in relaxin-3’s interaction with its endogenous receptor, 
RXFP3 [44] (Figure 3B). 
Kuei et al. conducted mutational studies replacing either Arg12, Ile15, Arg16, 
Ile19 or Phe20 with different combinations of Ala, Ser, Lys, Gly, Arg, Tyr or Val. The 
results confirmed the importance of the residues for binding to the receptors; Arg12, 
Arg16 and Ile19 seem to be especially important for relaxin-3 binding to RXFP1, 
which fits with the earlier reported relaxin binding RXXXRXXI motif [39]. Phe20 and 
Ile15 were shown to be important for relaxin-3 binding to RXFP3 and 4 [8, 44]. Phe20 
is not important for RXFP1-binding [40, 41, 44]. 
Kuei et al. also found that changing Arg8 to Ala or Ser resulted in lower 
potency and affinity for RXFP3, 4, and 1 [44]. It was suggested that Arg8 could be 
involved in stabilizing the overall structure of relaxin-3, as it is positioned close to the 
A-chain and may interact with it [44] (Figure 3B).  
Altering Arg26 to Ala or Thr, or Trp27 to Ala, Phe or Arg gave a dramatic 
reduction in agonist activity on both RXFP3 and 4 while the activity on RXFP1 was 
unchanged. Interestingly, binding affinity was not lost for either RXFP3 or 4, 
indicating that Arg26 and Trp27 are important for receptor activation, but not essential 
for binding [44]. 
 
Figure 4. Residues on the relaxin-3 B-chain important for binding and activation of the various 
RXFP receptors. Residues important for binding are shown in red, and residues crucial for 
activation of RXFP3 and 4 in green. 
 
The N-terminus was shown not to be important for binding as seven residues 
could be removed without significant loss of binding or activity. In all of these 
peptides, the A-chain was left unchanged [44]. The B-chain residues important for 
binding and activation of the various RXFPs are summarised in Figure 4. 
Although relaxin-3 and analogues containing both the A- and B-chains are 
able to bind to and activate all the RXFP-receptors, removing the A-chain changes 
this situation. Binding and activation of RXFP1 and 2 requires both the A- and B-
chains of the ligands [36, 40], while the B-chain alone can activate RXPF3 and 4 [36, 
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40, 45]. This, along with the unchanged activity on RXFP1 on altering Arg26 and 
Trp27, suggests that the activation domain for RXFP1 and 2 is located on the A-chain 
[36, 44]. As the primary binding site of RXFP1 and 2 is located in the leucine-rich 
extracellular domain of the receptor, it has been suggested that this secondary 
interaction, which activates the receptor involves the A-chain binding to the short 
extracellular loops [4, 32, 46]. 
Not much is known about the binding of INSL5 to RXFP4, and as it is 
difficult to synthesise [47], no analogues have been made. Based on expected 
similarity to the binding of relaxin-3 to RXFP4, it is assumed that Arg5, Ile12, Arg13, 
Ile16 and Tyr17 in INSL5 are important for binding to RXFP4 [7, 8]. 
INSL5 has the same C-terminal residues Arg and Trp as relaxin-3. These 
residues are in relaxin-3 the activation domain for both RXFP3 and 4. Interestingly, 
INSL5 activates RXFP4, but works as an antagonist on RXFP3 [7]. It has been 
suggested that this is because of structural differences between relaxin-3 and INSL5; 
in INSL5 the B-chain "-helical segment continues to the C-terminal Trp24, whereas it 
in relaxin-3 ends five residues earlier, with Cys22, placing the key Arg-Trp motif in a 
different position [7]. 
 
1.2.5. Relaxin peptide analogues 
 
Due to the important physiological roles of relaxins there is a clear potential 
for RXFP-receptor modulators as novel drugs. However, this requires issues both 
relating to the complex structure and the lack of selectivity of the native peptides to be 
addressed. Developing selective agonists and antagonists for the RXFP-receptors has 
become an intriguing field of research, both in order to get new tools to further 
investigate physiological roles, and to find potential drug leads [45, 48]. 
Relaxin-2 can be made specific for RXFP1 by truncation of TrpB28, which is 
required for RXFP2 binding [40, 43]. Making selective relaxin-3 analogues on the 
other hand, is more complex. The need for selective relaxin-3 analogues is especially 
important for further studies of its functional roles. Because of relaxin-3’s ability to 
activate all known RXFP-receptors, and because RXFP3 and RXFP1 are both 
expressed in the brain, selective ligands are important to study its effects without the 
results being confounded by cross binding to RXFP1 [44, 45, 49]. 
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Another aim in the design of new analogues is designing simpler peptides, to 
make synthesis easier and cheaper [45]. 
Liu et al. [48] developed a chimeric peptide that selectively activated RXFP3 
over RXFP1. The chimera R3/I5 consisted of the A-chain from relaxin-3 and the B-
chain from INSL5 [44, 48]. 
In 2007 Kuei et al. reported the discovery of a selective antagonist for RXFP3 
[44]. The antagonist R3(B#23-27)R/I5 is a chimeric peptide consisting of the B-chain 
from relaxin-3 and the A chain from INSL5. In addition to having an extra C-terminal 
Arg, the B-chain Gly23 was replaced by Arg, and the C-terminus truncated (Gly24-
Trp27 deleted) [44].  
The additional C-terminal Arg was not a planned design; it was discovered by 
chance that a non-native C-terminal Arg created a higher affinity antagonist, 
presumably by creating an additional interaction point [44, 45, 50]. Through in vitro 
pharmacological studies it was shown that R3(B#23-27)R/I5 binds to human RXFP3 
with high affinity, but lacks affinity for human RXFP1. In vivo studies on rats showed 
that R3(B#23-27)R/I5 administered intracerebroventricularly blocks food intake 
stimulated by the selective RXFP3-agonist, R3/I5 [44]. 
Building on this research Haugaard-Kedström et al. recently discovered that 
using only the B-chain of relaxin-3, they were able to develop a selective, single-
chain peptide antagonist for RXFP3 [45]. The antagonist R3 B1-22R is a truncated 
relaxin-3 B-chain, with the same C-terminal arginine [45] as in the R3(B#23-27)R/I5 
peptide discovered by Kuei et al. [44]. The native cysteines have been replaced by 
serine residues in this single-chain antagonist [45]. The new peptide R3 B1-22R was 
shown to bind to RXFP3 with similar affinity as native relaxin-3, and testing on 
functional cyclic adenosine monophosphate (cAMP) assays showed that R3 B1-22R 
was indeed fully selective for RXFP3 [45].   
Structural analysis by two-dimensional (2D) nucleic magnetic resonance 
(NMR) spectroscopy analysis suggested that the R3 B1-22R peptide lacks secondary 
structure, adopting a random coil conformation in solution [45]. This finding is 
consistent with previous assumptions that the A-chain supports the structure of the 
relaxin-3 B-chain, and removing the A-chain leaves the isolated B-chain with a 
compromised structure [44, 45, 49].  
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1.3. Helix-inducing strategies 
 
To further develop the R3 B1-22R peptide towards clinical use, it is critical to 
incorporate modifications that reintroduce its native helical structure in order to 
improve stability, and possibly binding affinity. Several strategies have previously 
been applied to other peptides, including the use of helical capping sequences and 
grafting of key residues into stable scaffolds [51, 52]. 
 
1.3.1. Helix capping  
 
Helices are stabilised by hydrogen bonds between i and i-4 residues, but at the 
helix termini, this hydrogen bond pattern ends. Some amino acids are favoured in 
these end-positions because they can form interactions that compensate for the 
disrupted hydrogen bond pattern, and particular sequences of these particular amino 
acids are referred to as helix caps [53]. 
It was recently shown for the vascular endothelial growth factor (VEGF) 
peptide that incorporating capping sequences at the start and end of a helical region 
that displayed key residues for receptor binding was able to induce a stable helical 
structure, without need for the rest of the peptide. This analogue retained the high 
affinity of the native peptide for the VEGF receptor [51]. In this study, single-chain 
relaxin analogues using a similar capping sequence as in the VEGF peptide were 
designed to investigate whether this approach is applicable for relaxins. 
 
1.3.2. Using chlorotoxin as a scaffold 
 
A promising approach for designing bioactive peptides with desirable 
properties is to identify key residues for the function of a particular peptide, and then 
graft these residues onto a different peptide with similar structure but more desirable 
chemical properties, such as high stability [52]. 
Chlorotoxin is a 36 amino acid neurotoxic peptide from the venom of the 
scorpion Leiurus quinquestriatus [54]. Upon discovery it was thought to selectively 
bind to chloride channels, hence the name chlorotoxin [54]. Synthetic chlorotoxin is 
also known as TM601 [55]. Recently it has been discovered that the molecular target 
for the chlorotoxin peptide is Annexin A2, and not chloride channels as originally 
thought [56].  
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Chlorotoxin has four disulfide bonds, giving it a highly folded, stable structure 
[57, 58]. It has an overall structure of a small three-stranded antiparallel ! -sheet 
packed against an "-helix. Three of the disulfide bonds cross link the "-helix to the !-
sheet, while the fourth disulfide links the N-terminal to the rest of the molecule [57] 
(figure 5).  
 
 
Figure 5. Solution NMR structure of chlorotoxin. Disulfide bonds are shown in yellow. 
 
Chlorotoxin has tumour-binding properties, and is able to bind specifically to 
various tumour cells. Because of this, chlorotoxin has been combined with various 
molecules to create probes to aid in localisation of tumours during surgery [55]. 
Among the tumour imaging tools currently under investigation is a 131I –radiolabeled 
chlorotoxin analogue, and a CTX:Cy5.5 dye bioconjugate [55]. 
As the putative drug target RXFP3 is mainly expressed in the brain, 
chlorotoxin’s abiliy to cross the blood-brain barrier makes it highly desirable as a 
scaffolding molecule. In an alanine scan of chlorotoxin, all mutants were assumed to 
cross the blood-brain barrier as they showed similar activity to the native peptide 
(Muharrem Akcan, unpublished data). An analogue with chlorotoxin used as a 
scaffold might therefore still be able to penetrate the blood brain barrier.  In addition 
to the physiological properties, chlorotoxin has an " -helix with a suitable size for 
incorporating the important residues for binding to RXFP4 [57]. All of these 





1.4. Combinational libraries 
 
The finding that introducing a non-native arginine at the C-terminus of a 
truncated relaxin-3 B-chain increases the affinity of this antagonist analogue > 100-
fold [44, 45] highlights that small changes, including replacement of single amino 
acids can have a major impact on the affinity of a ligand if a favourable new contact 
point with the receptor is introduced. Methods have been described to rationally 
search for such favourable mutations, including the synthesis of combinational 
libraries where mixtures are coupled at one or several positions in the sequence [59]. 
By testing the mixtures, or fractions thereof, the identity of high affinity analogues 
can be identified if present. 
Several residues are exposed adjacent to the primary binding residues in 
relaxin-3 and its single-chain antagonist, and there is potential to further improve the 
binding to RXFP3 by modifying these. In this study we investigated the effect of 
replacing Glu13 in the R3 B1-22R antagonist with 16 different amino acids (excluding 
cysteine, methionine, glycine and proline). 
 
1.5. Aims for the project 
 
In this project we aimed to design relaxin peptide analogues where a helical 
structure is induced around the receptor-binding region. The hypothesis is that a stable 
helical structure resembling the native peptide will give higher affinity analogues. 
o Capping sequences were used to induce helices in short single-chain analogues. 
Capped single-chain analogues were designed as relaxin-3 agonist, relaxin-3 
antagonist, relaxin-2 antagonist, INSL5 agonist and INSL5 antagonist. 
o Chlorotoxin was used as a scaffold, and an analogue with the amino acids 
important for relaxin-3 binding to RXFP3 were incorporated into the existing 
helical region of chlorotoxin. 
 
Additional aims were: 
o To investigate the importance of Arg8 in a single-chain analogue by replacing 
Arg8 in the R3 B1-22R antagonist with alanine, and to probe for other mutations 
that might give an increase in affinity similar to the non-native Arg23 in R3(B#23-








The design of the capped relaxin analogues was based on a capped analogue of 
the VEGF peptide, in which a stable helix was successfully introduced by 
incorporating helix capping sequences [51]. In this study, we have investigated 
whether this approach might also be applicable to single-chain analogues of relaxins. 
Our hypothesis was that if a stable helical structure can be achieved, it will give a 
receptor modulator with higher affinity than previous single-chain analogues, because 
it will more closely resemble the structure of the native peptides. 
As shown in Figure 6, the N-terminal capping sequence KLT was introduced 
in all of the analogues, based on the success of the VEGF peptide analogue. The C-
terminal capping sequence KGI is used as in the VEGF peptide for the relaxin-2 and 
INSL5 antagonists, whereas it is offset by one residue for the relaxin-3 and INSL5 
agonists. This was done to utilise the existing glutamic acid’s position in the sequence  
which would be expected to further support the capping sequence. In the relaxin-3 
antagonist analogue, the C-terminal capping sequence was left out to avoid affecting 
the non-native C-terminal arginine known to provide an extra interaction point with 
the receptor [44, 45, 50]. The introduced glutamic acid in position six, as well as the 
leucine and the glutamine, are also found to favour helix stabilisation, due to the 





Figure 6. Amino acid sequences of capped analogues designed to act as agonists and antagonists 
on RXFP receptors. Capping sequences are adapted from a capped analogue of the VEGF 
peptide. 
 
2.1.2. Synthesis and cleaving 
 
Synthesis of all capped relaxin analogues was done using 9H-fluoren-9-
ylmethyloxycarbonyl (Fmoc) chemistry on a Rink-Amide MBHA resin. All peptides 
except the INSL5 agonist were synthesised on an automated CEM Liberty microwave 
synthesiser. The INSL5 agonist was synthesised manually with an average coupling 
yield of approximately 99.4 %. 
The peptides were cleaved from the resin using Trifluoracetic acid (TFA), and 
Electrospray mass spectrometry (ES-MS) was used following cleavage to confirm 
that the correct peptide was present from each synthesis.  
For the relaxin-2 and INSL5 antagonists, the major peaks in the mass spectrum 
corresponded to the desired product. For the relaxin-3 antagonist, relaxin-3 agonist 
and the INSL5 agonist the major peaks belonged to side products. As the peptides 
were successfully purified with acceptable yield, and due to time constraints, the 
identity of the side products was not determined. For the INSL5 agonist the yield after 
purification was low, which might be a result of low synthesis yield due to side 
product formation. 
The INSL5 antagonist, relaxin-2 antagonist, relaxin-3 antagonist analogues 




Using reverse phase high performance liquid chromatography (RP-HPLC), all 
peptides were successfully purified with the following results: 
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Relaxin-2 antagonist 
The peptide eluted after approximately 36 minutes on a 1% gradient, 8 ml/min 
program, using a preparative C18 column (see section 5.4.1). The mass of pure 
peptide was 56.69 mg, and the yield 33.7 %. ES-MS spectra and HPLC 
chromatogram for the relaxin-2 antagonist are shown in Figure 7. The spectra and 
chromatograms for the other capped analogues are found in the appendix, Figure A1-
A2. 
Relaxin-3 antagonist 
The peptide eluted after approximately 38 minutes with on a 1% gradient, 8 
ml/min program, using a preparative C18 column. The mass of pure peptide was 3.08 
mg, and the yield 1.7 % 
INSL5 antagonist 
The peptide eluted after approximately 41 minutes on a 1% gradient, 8 ml/min 
program, using a preparative C18 column. The mass of purified peptide was 25.7 mg, 
and the yield 12.7 %. 
Relaxin-3 agonist 
ES-MS after cleaving of the relaxin-3 agonist showed that masses 
corresponding to the peptide were present in both the A/B phase and the ether phase. 
Both the A/B- and the ether phase were purified by RP-HPLC. The ether phase gave 
the purest fractions after the first purification, and was further purified. 
The peptide eluted after approximately 44 minutes on a 1% gradient, 8 ml/min 
program, using a preparative C18 column. The mass of purified peptide was 2.68 mg, 
a yield of 1.4 %. 
INSL5 agonist 
The peptide was purified by RP-HPLC, and needed two purifications to be 
sufficiently pure. The peptide eluted after approximately 47 minutes on a 1% 
gradient, 8 ml/min program, using a preparative C18 column. The mass of pure 
peptide was only 0.04 mg, a yield of 0.012 %. 
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Figure 7. Purification  and characterisation of the capped relaxin-2 antagonist. A) ES-MS 
spectrum after TFA cleavage showing major masses belonging to the peptide. B) RP-HPLC trace 
of the purified peptide. C) ES-MS spectrum of purified peptide, confirming that the correct 
peptide is present. 
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2.1.4. Structural studies 
 
Structural analysis of the capped relaxin analogues was performed by 
recording and assigning 2D NMR spectra of the purified peptides. The spectra were 
assigned using the sequential assignment procedure [60]. Figure 8 shows the total 
correlation spectroscopy (TOCSY) and nuclear Overhauser effect spectroscopy 
(NOESY) spectra recorded for the relaxin-2 antagonist. The individual amino acids 
were identified in the TOCSY spectrum (figure 8, A), and the connections between 
the residues determined by the NOESY cross-peaks (figure 8, B). 
Non-sequential cross-peaks were observed in the NOESY spectrum; 7H" to 
10HN and 3H" to 5HN are labelled in figure 8. Additional non-sequential peaks were 
observed for the relaxin-2 antagonist, as well as in the spectra of some of the other 
analogues (data not shown). 
To get an indication of the structure of the peptides, secondary H! chemical 
shifts were calculated. Secondary H! chemical shifts are the difference between the 
observed H!-shift of a residue and the chemical shift of the same residue in a peptide 
with a random coil structure [61]. A sequence of negative shifts is indicative of an !-





Figure 8. NMR spectra of the relaxin-2 antagonist. A) TOCSY spectrum with the individual spin 
systems indicated by green lines. Residue numbers are given by numbers above the lines. B) 




From the secondary H! chemical shifts shown in Figure 9, the capped 
analogues display a general tendency towards negative shifts, indicating a helical 
structure. The relaxin-2 and INSL5 antagonists display particularly negative shifts 
from residue four to seven. 
The secondary structure of the relaxin-2 antagonist was calculated (Figure 10) 
in order to determine if the helical tendencies seen from the secondary H! chemical 
shifts correlated with a well defined helical structure. The structure did show two 
helical turns close to the N-terminus, whereas the C-terminus is mainly unstructured. 
 
Figure 9. The secondary H!  chemical shifts of the capped relaxin analogues. The secondary H!  
shifts were calculated by subtracting the random coil shifts from the experimental H!  shifts. 
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Figure 10. NMR structure of the capped relaxin-2 antagonist. The arginines 13 and 17 (blue) and 
the isoleucine 20 (red) in the relaxin binding motif are labeled according to their position in 
native relaxin-2 
 
2.1.5. Binding and activity 
 
In competitive binding assays on cells expressing RXFP-receptors, all of the 
capped analogues showed little or no binding to the receptors (Figure 11). Consistent 
with the lack of binding, the INSL5 analogues also failed to show any activity, 
measured by the ability to reduce forskolin induced cAMP activity in a cell based 
activity assay (Figure 12). Unfortunately, the activity assay on the relaxin-3 agonist 
was not completed in time to be included in this thesis. 
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Figure 11.  Competition binding curves for capped relaxin B-chain analogues in comparison to 
Eu-R3/I5, Eu-relaxin-2 or Eu-INSL5. 
 
Figure 12. Agonist or antagonist activites of capped INSL5 analogues, measured by changes in 
cAMP activity. 
 
2.2. R3 B1-22R R8A analogue 
 
2.2.1. Synthesis and purification 
 
In light of the lack of activity of the capped analogues, we considered whether 
additional features outside the helical segments were involved in the receptor 
interaction of relaxin-3. Arg8 is a conserved residue, and appears to play a role in the 
activity of native relaxin-3. Therefore we decided to make an alanine-mutated variant 
testing this hypothesis. 
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The synthesis of the R8A mutant of the R3 B1-22R analogue was performed 
on an automated CEM Liberty microwave synthesiser using Fmoc chemistry. The 
peptide was cleaved from the resin using TFA. 
ES-MS after cleaving showed that the masses corresponding to the peptide 
were present in both the A/B phase and the ether phase. Both phases were freeze-
dried, and purified by RP-HPLC. The ether phase yielded sufficiently pure fractions 
after one round of purification. The mass of pure peptide was 23.64 mg, resulting in a 
yield of 12.7 %. ES-MS spectra and HPLC chromatogram are shown in the appendix, 
figure A3. The peptide eluted after approximately 46 minutes on a 1% gradient, 8 




Competitive binding assay on the R8A analogue of R3 B1-22R showed a loss 
of affinity in the alanine mutant. However, it still has affinity for RXFP3 (Figure 13). 
 
Figure 13. Competition binding curves for R8A analogue of R3 B1-22R in comparison to the 
parent peptide and native relaxin-3. Competitive binding was measured using Eu-R3/I5 in 
RXFP3 expressing cells 
 




The relaxin-3/chlorotoxin analogue was designed by incorporating the 
residues known to be important for relaxin-3 binding to RXFP3 into the existing 
helical segment of chlorotoxin (figure 14). In light of our results showing that the 
R8A mutant of the R3 B1-22R peptide had decreased affinity compared to the parent 
peptide, an arginine was incorporated in a position outside the helix, similar to that 
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found in position eight of native relaxin-3. The sequence of native chlorotoxin 
compared to the relaxin-3/chlorotoxin analogue is shown in Figure 14. 
 
 
Figure 14. The amino acid sequence of native chlorotoxin and  an analogue where the 
residues important for binding to RXFP3 have been grafted into chlorotoxin. Disulfide bonds 
in the native fold of the peptide are indicated by connecting lines. 
 
 
2.3.2. Synthesis and purification 
 
The synthesis of the chlorotoxin analogue was performed on an automated 
CEM Liberty microwave synthesiser using Fmoc chemistry. The peptide was cleaved 
from the resin using TFA. ES-MS on the crude peptide showed major peaks in the 
mass spectrum that corresponded to the mass of the peptide. 
The peptide was purified by RP-HPLC on a preparative C18 column, using a 
1% gradient before folding. The peptide eluted after approximately 38 minutes on a 
1% gradient, 8 ml/min program, using a preparative C18 column. The mass of 

















A small-scale folding trial was done, investigating a range of folding 
conditions. The peptide concentration in all buffers was 0.1 mg/mL. The following 
conditions were used: 
1 0.1 M Tris-HCl 
0.2 M NaCl, 5 mM reduced glutathione 
0.5 mM oxidized glutathione 
pH 7.8 
2 0.1 M NH4OAc 
pH 8.3 
3 0.1 M (NH4)2CO3 
pH 8.2 
4 0.33 M NH4OAc 
0.5 M GnHCl 
5 0.1 M Na3PO4 
pH 7.4 
6 Buffer 1/isopropanol, 1:1 
7 Buffer 2/isopropanol, 1:1 
8 Buffer 3/isopropanol, 1:1 
9 Buffer 4/isopropanol, 1:1 
10 Buffer 5/isopropanol, 1:1 
 
After 24 hours, analytical HPLC was used to analyse the samples. All samples 
showed the same general pattern with a sharp, early eluting peak, followed by a broad 
collection of peaks presumably containing misfolded peptide (figure 15). The 
buffer/isopropanol mixtures showed the lowest intensity of the earliest eluting peak. 
After 48 hours, analytical HPLC was used to analyse the five samples without 
isopropanol. Results and conditions are summarised in figure 15. Again, the same 
pattern was seen, and the extra oxidation time did not seem to have affected the 




Figure 15. The oxidation conditions examined for the relaxin-3/chlorotoxin analogue. RP-HPLC 
chromatogram after a small scale oxidation trial. 
 
In the small scale folding trial the 0.1 M sodium phosphate buffer (pH 7.4) 
seemed to give the most intense and cleanest peak in the HPLC-trace (figure 15). 
A buffer with 0.1 M Tris-HCl, 0.2 M NaCl, 5 mM reduced glutathion, 0.5 mM 
oxidized glutathion (pH 7.8) has previously been successfully used on native 
chlorotoxin, and both these buffers were used for further folding of the peptide. 
 
After folding, the peptide was purified using RP-HPLC on a 3 ml/min column 
and a 0.5 % gradient. After five rounds of oxididation and purification of 5-18 mg 
reduced, pure peptide at a time, a mass of 1.52 mg pure, oxidized peptide was 
obtained. A total of 62.65 mg of R3/CTX was oxidized. This gives a 2.43 % yield 
after oxidation, and a total yield of 0.2 %. Analytical RP-HPLC chromatograms and 




Figure 16. Purification and folding of relaxin-3/chlorotoxin analogue. A) ES-MS spectrum after 
TFA cleavage showing major masses belonging to the peptide. B) ES-MS spectrum of purified 
reduced peptide. C) RP-HPLC chromatogram from oxidation trial using 0.1 M sodium 
phosphate buffer (pH 7.8). D) RP-HPLC chromatogram of the purified, oxidized peptide. E) ES-





H NMR of oxidized R3/CTX analogue 
 
To check whether the major isomer of the peptide was correctly folded, the 
purified peptide was analysed by 1H NMR (600 MHz). The recorded spectrum 
compared to that of native chlorotoxin is shown in Figure 17. 
 
Figure 17. Comparison of the 1D NMR spectra of the relaxin-3/chlorotoxin analogue (blue) and 
native chlorotoxin (red). The spectra indicate that the relaxin-3/chlorotoxin analogue has 
adopted a chlorotoxin-like fold. 
 
The sample analysed was small, giving very low intensity peaks, but through a 
large number of scans the signal-to-noise ratio was sufficiently increased to give an 
indication of the fold. As shown in Figure 19, the signals appear to be well dispersed, 
with several down field shifted peaks indicating a folded peptide. 
 




Based on the accidental discovery that a non-native C-terminal arginine can 
create an additional contact point with the RXFP3 receptor [44, 45, 50], it was 
decided to do a targeted probing to potentially reveal other positions and mutations 
that could enhance receptor binding.  
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Glu13 in the relaxin-3 B-chain is in a position close to other residues that are 
important for binding to RXFP3, and this residue was chosen as a position that might 
be used to create additional interaction points. 
A combinational library of R3 B1-22R was synthesised using a mixture of 16 
different amino acids (cysteine, methionine, proline and glycine excluded) in the 
position of Glu13. Cysteine and methionine were left out to simplify the process by 
eliminating potential problems with disulfide formation by cysteines in different 
peptide molecules, and oxidation of the methionine. Glycine and proline were 
excluded from the mixture because these residues would break any helical tendencies 
shown by the peptide, which would most likely cause a loss of affinity. 
 
2.4.2. Synthesis and bioactivity guided fractionation 
 
The E13 mix was synthesised by Richard Clark on an automated CEM Liberty 
microwave synthesiser, using Fmoc chemistry. The synthesis of the E13 analogues 
was done by using a mixture of amino acids at position 13, while following standard 
solid phase peptide synthesis procedures on the rest of the peptide. This resulted in a 
mixture of peptides differing in residue 13. The peptides were cleaved from the resin 
using TFA. 
A bioactivity guided fractionation approach was used to separate the crude 
mixture. The results from this approach are summarised in figure 18. 
 
Figure 18. Summary of procedure and results from the bioactivity guided fractionation approach 




Fractionation was based on retention times on RP-HPLC, and bioactivity determined 
by competitive binding assays (see section 5.7.2). 
The binding assay on the mixture showed loss of binding compared to R3 B1-
22R, but there was still affinity for RXFP3 (Figure 19). To determine whether this 
affinity was due to one high affinity analogue, or several weakly binding analogues it 
was decided to divide the mixture into rough fractions to do further binding assays. 
This was done by RP-HPLC. The RP-HPLC chromatogram showed a broad peak 
between 28-60 minutes (figure 20, A) and fractions collected in this period were 
roughly divided into four pools. The fraction collected between 28 and 48 minutes did 
not have any significant mass after freeze drying, and was not used any further. 
Binding assays were done on the other three fractions, and all three fractions showed 
increased affinity compared to the original mixture. However, fractions collected 
between 49 and 61 minutes, and between 61 and 70 minutes bound with slightly 
higher affinity (Figure 19).  
 
 
Figure 19. Competition binding curves for fractions after RP-HPLC on a mixture of R3 B1-22R 
analogues with mutations at position 13. Affinity shown in comparison to the parent peptide and 
the original crude E13 mixture. Competitive binding measured using Eu-R3/I5 in RXFP3 
expressing cells   
 
These fractions were then further divided by RP-HPLC on a 0.25 % gradient 
(Figure 20, B-C), and the fractions analysed by ES-MS, and combined according to 
the masses each fraction contained. Through ES-MS analysis we were also able to get 
an indication as to which analogue of R3 B1-22R that was found in the different 
fractions. 
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The fractions found to contain peptides were then tested for binding to 
RXFP3, and fractions B.5 and B.7 showed similar or slightly increased affinity 
compared to R3 B1-22R (figure 21). 
 
 
Figure 20. RP-HPLC traces of the combinational library of the R3 B1-22R peptide with 
mutations at the position of E13. A) The original E13 mixture B) fractions collected between 38 




Figure 21. Competition binding curves for final fractions after RP-HPLC on a mixture of R3 B1-
22R analogues with mutations on position 13. Affinity shown in comparison to the parent peptide 
and the original crude E13 mixture. Competitive binding measured using Eu-R3/I5 in RXFP3 




Matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) MS 
was performed on the two fractions that showed a possible increase in affinity 
compared to R3 B1-22R, in order to determine which analogues were in those 
samples. Fraction B.7 showed two major peaks with monoisotopic masses of 2593.7 
and 2620.7 (figure 22, D). These masses correspond to E13T and E13Q or E13K, 
respectively. Fraction B.5 had one major peak with a monoisotopic mass of 2562.7 
(figure 22, B). This monoisotopic mass is one mass unit off compared to the 
theoretical monoisotopic mass of the E13A analogue, but as there are no other 
analogues with mass close to E13A (see table 1), this peptide is likely to be the E13A 
analogue. 
 







E13G 2548,45 2549,45 2550 
E13A 2562,46 2563,46 2564,02 
E13S 2578,46 2579,46 2580,02 
E13P 2588,48 2589,48 2590,06 
E13V 2590,49 2591,49 2592,08 
E13T 2592,47 2593,47 2594,05 
E13L 2604,51 2605,51 2606,1 
E13I 2604,51 2605,51 2606,1 
E13N 2605,47 2606,47 2607,05 
E13D 2606,45 2607,45 2608,03 
E13Q 2619,48 2620,48 2621,07 
E13K 2619,52 2620,52 2621,12 
E13H 2628,48 2629,48 2630,08 
E13F 2638,49 2639,49 2640,12 
E13R 2647,53 2648,53 2649,13 
E13Y 2654,49 2655,49 2656,12 
E13W 2677,5 2678,5 2679,16 




Figure 22. Spectra from MALDI-TOF-MS of fraction B.5 (panels A-B) and fraction B.7 (panels 
C-D). Panels A and C show the full spectrum, and panels B and C a selected range showing the 
isotope pattern of the E13 analogues present in the samples. 
 
Both the samples we used for MALDI-TOF MS were impure, and as there 
were insufficient amounts for repurification, it was decided to synthesise one of the 




2.5. Synthesis, purification and binding of the E13A analogue 
of R3 B1-22R 
 
The synthesis of the E13A mutant of the R3 B1-22R analogue was performed 
on an automated CEM Liberty microwave synthesiser using Fmoc chemistry. The 
peptide was cleaved from the resin using TFA. 
Extraction of the peptide from the ether phase was not complete and ES-MS 
on both phases showed major peaks corresponding to the mass of the peptide. Both 
phases were freeze-dried and the peptide was successfully purified by RP-HPLC. 
The peptide eluted after approximately 44 minutes on a 1% gradient, 8 ml/min 
program, using a preparative C18 column. After purification the mass of pure peptide 
was 13.68 mg, giving a yield of 4 %. ES-MS spectra and HPLC chromatogram are 
shown in the appendix, figure A3. 
As shown in Figure 23, the competitive binding assay on the E13A analogue 
of R3 B1-22R seemed to bind with slightly higher affinity compared to the parent 
peptide. The affinity is very similar to that shown by fraction B.5 (Figure 21). 
 
Figure 23. Competition binding curves the E13A mutant of R3 B1-22R. Competitive binding 
measured using Eu-R3/I5 in RXFP3 expressing cells   
 
2.6. Synthesis and purification of R3 B1-22R 
 
The R3 B1-22R analogue was synthesised to use as a positive control in the 
binding assays for RXFP3. The synthesis was performed on an automated CEM 
Liberty microwave synthesiser using Fmoc chemistry. The peptide was cleaved from 
the resin using TFA. 
ES-MS on the crude peptide showed major peaks corresponding to the mass of 
the peptide. The peptide was purified by RP-HPLC, and three purification runs were 
needed to get a pure peptide. The peptide eluted after approximately 48 minutes on a 
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1% gradient, 8 ml/min program, using a preparative C18 column. The mass of 
purified peptide was 3.92 mg, giving a yield after purification of 2 %. ES-MS spectra 


































Relaxins have a complex structure with two chains interlinked by disulfide 
bonds [4, 5, 40], making them difficult to synthesise [45]. They also show a 
complicated binding pattern to the relaxin family receptors, lacking high selectivity 
for individual receptors [8, 21, 30-34, 37]. As the RXFPs are promising drug targets 
for a range of diseases [4, 5, 13], designing simpler and selective analogues is 
desirable. One particularly promising analogue is the selective antagonist R3 B1-22R, 
which binds to RXFP3 with high affinity. This analogue is however mainly 
unstructured in solution [45]. To further develop single-chain analogues of the relaxin 
family peptides as drug leads, being able to reintroduce the helical structure of the 
native peptides is paramount. A structured peptide will have increased stability 
compared to a random coil analogue [63, 64], and reintroducing a native helical 
structure around the receptor-binding region is likely to improve affinity. 
The receptor-binding site of relaxin-3 and INSL5 is believed to be located in 
the B-chain alone, but without the structural support of the A-chain these molecules 
have poor affinity for their receptors [36, 40, 45]. Therefore, in this study we have 
explored the possibility of introducing a stable helical structure around the receptor-
binding region. We investigated the use of helix capping sequences for stabilising the 
B-chain key helical region in the absence of an A-chain. This strategy did induce 
some helicity, however it was not sufficient to generate high affinity analogues for 
any of the receptors. We have shown that this might in part be explained by the 
removal of Arg8, which appears to be more involved in receptor interaction than 
previously believed. In a second approach, the key receptor binding residues of 
relaxin-3, including Arg8, were grafted onto a stable disulfide-rich peptide; 
chlorotoxin. We were able to successfully synthesise the relaxin-3/chlorotoxin 
analogue, but the yield after oxidation was low and we were not able to get any 
information about structure or bioactivity within the time limits of the project.   
Finally, by synthesising libraries of the RXFP3 antagonist R3 B1-22R, we 
investigated the possibility of identifying additional contact points close to the 
residues known to be involved in binding. We were able to successfully synthesise a 
library of peptides with mutations in position 13, and by a bioactivity guided 
fractionation approach and MS we were able to separate out the more active 
analogues. However, we did not find any mutants with especially high activity. 
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3.1. Capped relaxin analogues 
 
Capping sequences that have previously been successfully applied on the 
VEGF peptide [51] were used as a template in designing capped analogues of relaxin-
2, -3 and INSL5. For the VEGF peptide these caps were sufficient to introduce a fully 
stable helical conformation [51], suggesting that a similar strategy may be applicable 
to relaxins. The capping sequences were adapted around the residues present in the 
binding region of the B-chains of the selected peptides. 2D NMR spectroscopy 
experiments were used to get an indication of secondary structure in the peptides. All 
of the capped analogues displayed generally negative secondary shifts, indicating a 
helical structure. Compared to the secondary H! chemical shifts seen in the R3 B1-
22R peptide [45], there is a general tendency towards increased helical properties in 
the capped analogues. However, the helical tendency is not as strong in the native 
relaxins. A few non-sequential nuclear Overhauser effects (NOE) were observed in 
the spectra, however not to the extent expected for a stable helical conformation, and 
what is seen in the native two-chain relaxin peptides. 
Of the analogues showing the most helical structure, the spectra of the capped 
relaxin-2 antagonist appeared to be of the highest quality. The spectra recorded for the 
relaxin-2 antagonist were therefore used to calculate a three dimentional (3D) 
structure of the peptide, in order to further investigate the effect of the capping 
sequences on the secondary structure. From the structure of the relaxin-2 antagonist, 
we learned that the N-terminal capping sequence had introduced two helical turns to 
the peptide. This led to the two arginines in the relaxin-binding motif being positioned 
correctly; exposed next to each other on the same face of the helix. The C-terminal 
cap, on the other hand, was not able to introduce structure. This resulted in disruption 
of the helix, with the position of the isoleucine essential for binding being positioned 
significantly different compared to the native peptide. 
All analogues were tested in cell-based assays for binding and activation of 
their respective receptors. However, in the competitive binding assays performed on 
Chinese hamster ovary (CHO) and Human embryonic kidney (HEK2293) T cells 
stably transfected with the receptors, only the relaxin-3 antagonist and agonist showed 
any affinity for its receptor, and even for this analogue the binding was very poor. 
Functional cAMP assays on the INSL5 analogues showed no response of either the 
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agonist or the antagonist. Unfortunately, the functional cAMP assay was not 
completed in time to be included in this thesis. 
Relaxin-2 is known to have residues involved in binding in both the A and the 
B-chain [36, 39, 41, 65], making design of single-chain analogues more complicated. 
The capped single-chain analogue was therefore never expected to bind with similar 
affinity as the native peptide. However, if a stable helix is successfully introduced, it 
should in theory have measurable affinity, and be a good starting point for further 
modifications towards a drug lead. 
For relaxin-3 and INSL5, all residues important for binding are located in the 
B-chain [7, 8, 36, 40, 41, 45]. Based on this, a single-chain analogue containing the 
residues important for binding to the receptors should be able to bind at least weakly, 
even if it lacks secondary structure. Consequently, the extent of the loss of binding in 
the capped analogues was somewhat surprising.  
The main difference between the R3 B1-22R peptide and our capped 
analogues, apart from the capping sequences, was an N-terminal truncation of 
residues 1-8. The only residue in the removed sequence that has been shown to affect 
binding of relaxin-3 is Arg8. The binding of the relaxin-3 agonist and antagonist is 
even poorer than that seen for the relaxin-3 B-chain alone. This further supports the 
hypothesis that the lack of binding is due to more than a lack of structure. Arg8 has 
previously been thought to affect binding mainly by stabilising the fold of the native 
peptide, not by binding to the receptor [44]. This led to a discussion of whether Arg8 
is more involved in binding of a single-chain analogue than previously thought. To 
further investigate, an R8A mutant of R3 B1-22R was synthesised as described in 
previous sections. The results from the competitive binding assay showed that the 
R8A mutant had lower affinity for RXFP3 compared to the R3 B1-22R peptide. 
However, it still retained higher affinity than the capped relaxin-3 antagonist. The loss 
of binding in removing the Arg8 does not account for all of the lost affinity in the 
capped analogue, and since the capped analogue did have more of a helical structure 
than R3 B1-22R, this suggests that there may be additional binding sites in the N-
terminal part of the relaxin B-chain. The residues that were replaced by the capping 
sequences might also have been more involved in binding than assumed. 
Additionally, the introduction of the capping sequences might have resulted in 
different chemical properties at the receptor-binding site, compromising the affinity. 
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If capped single-chain relaxin analogues are to be further developed, different 
C-terminal capping sequences should be investigated, seeing as the sequence used in 
the VEGF peptide did not introduce stable helices in the relaxin-analogues. 
Additionally, future capped analogues including Arg8 could further illuminate its role 
in a single-chain analogue. 
Another approach in designing a stable helical analogue is the use of lactam-
bridges to stabilize the helix. By bridging residues positioned on the side of the helix 
not involved in the receptor interaction, the structure could be stabilised. 
Future studies should also include mutational studies to further investigate the 
importance of the various residues in the B-chain, especially around the N-terminus. 
 
3.2. Relaxin-3/chlorotoxin analogue  
  
In light of the findings that Arg8 appears to be involved in receptor binding, 
and that the helix capping sequences used were insufficient to introduce a stable 
helical structure, we decided to investigate the use of stable scaffold molecules. The 
amino acids involved in binding, including Arg8, were grafted onto the helical region 
of the peptide chlorotoxin. 
 
3.2.1. Synthesis and oxidative folding 
 
RXFP3, the endogenous receptor for relaxin-3, is mainly expressed in the 
brain [21], and a potential drug lead targeting this receptor needs to be able to 
penetrate the blood-brain barrier to reach its proposed site of action. Native 
chlorotoxin is able to pass the blood-brain barrier, and an alanine-scan of chlorotoxin 
showed that all mutants were still able to penetrate the blood-brain barrier (Muharrem 
Akcan, unpublished data), suggesting that chlorotoxin used as a scaffold might still 
maintain this property.  
Structurally, chlorotoxin has a helix of a similar size to that found in the 
relaxin-3 B-chain [6, 57], making grafting of the residues important for RXFP3 
binding possible while still maintaining the helical structure. In addition, its structure 
allows for Arg8 to be grafted into a position similar to that in native relaxin-3, outside 
of the helix [6]. 
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Chlorotoxin is also a very stable molecule, showing high stability both in vivo 
and in vitro [58]. Because of these structural and physiological properties, a 
successful relaxin-3/chlorotoxin grafted analogue would make an excellent drug lead. 
The relaxin-3/chlorotoxin analogue was synthesised and oxidized as described 
in previous sections. From the folding trial the buffers containing isopropanol gave 
very low yield of the isomer thought to be the correctly folded peptide. Isopropanol 
favours folding of hydrophobic peptides, and as the more hydrophilic, correctly 
folded, peptide elutes earlier in RP-HPLC, these results are to be expected. 
The yield after oxidation and purification by RP-HPLC was very low, but 1H-
NMR on a small sample of purified, oxidized peptide showed a well-dispersed 
spectrum, correlating well with that seen in native chlorotoxin, suggesting the peptide 
was indeed correctly folded. A pure sample of 1.5 mg peptide was obtained, and the 
intention was to test for bioactivity and do structural analysis by 2D NMR. A one-
dimentional (1D) NMR however, showed very low intensity peaks, and performing 
any 2D NMR spectroscopy was not possible. ES-MS on the sample showed peaks 
with masses corresponding to the peptide, confirming that there was peptide present 
in the sample. Because of the low signal in the NMR spectroscopy experiments, this 
led us to believe that the peptide might be aggregating, preventing further structural 
characterisation. Further studies will have to be undertaken to confirm that a native 
disulfide arrangement had been achieved, and to generate sufficient material for 
functional testing. 
 
3.3. E13 combinational library of R3 B1-22R 
 
A different strategy to improve binding of single-chain analogues is to utilise 
residues that are not part of the native interaction with the receptor, but are close 
enough to the receptor-binding site to be able to form new contacts if modified. 
The selective RXFP3 antagonist R3 B1-22R is able to bind with high affinity 
despite its lack of structure because of an additional contact point with the receptor 
provided by the non-native C-terminal arginine [44, 45, 50]. This introduced residue 
improves affinity "100-fold compared to the relaxin-3 B-chain alone [44, 45]. Studies 
have shown that rapid identification of favourable “mutations” is possible by 
synthesising chemical libraries of analogues that include mixtures of different amino 
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acids at one or several points. Among other things this strategy has been used to 
improve the affinity of conotoxins for their target receptor [59].  
We identified E13 as a position that may be used to improve receptor binding 
in the R3 B1-22R analogue. A combinational library was successfully synthesised, 
with a mixture of amino acids inserted at position 13. LC-MS analysis revealed the 
presence of all expected masses confirming that the coupling of the mixture had been 
successful. After fractionation by RP-HPLC we were able to identify analogues with 
varying degrees of affinity for the RXFP3 receptor. None of the identified analogues 
were significantly more potent than the parent peptide, but some of the analogues 
apppeared to have slightly improved binding. Thus, an E13A variant that appeared to 
bind with the highest affinity was synthesised and tested. The synthesised analogue 
had comparable binding to that shown by the B.5 fraction. Thus, a pure analogue did 
not yield a higher affinity analogue. 
While it was disappointing that we were not able to identify any analogues of 
especially high activity, these results were encouraging in that we have proven the use 
of peptide mixtures in automated synthesis to be a possible method for synthesis of 
combinational libraries. We were also able to readily fractionate and test these 
mixtures to identify components with varying degree of binding. Future studies 





By utilising capping sequences, the helical character of single-chain analogues 
was successfully increased compared to native relaxin B-chains alone, and previous 
single-chain analogues. However, the capping sequences were not sufficient to 
introduce a stable helix. 
The capped relaxin-3 antagonist was found to bind RXFP3 with lower affinity 
than the parent peptide R3 B1-22R, despite a more helical structure. This finding 
implies that further residues than those known are involved in receptor binding. An 
R8A analogue of R3 B1-22R was synthesised, and binding assays confirmed that 
Arg8 is likely to be more involved in binding than previously thought. 
We were able to successfully synthesise a relaxin-3/chlorotoxin analogue, 
incorporating the residues important for binding to RXFP3 into the stable scaffold 
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created by the chlorotoxin structure. From 1D NMR data the analogue seemed to fold 
correctly. However, the yield following oxidation was poor, and no bioactivity data or 
structural data confirming the correct fold was obtained within the time limits of the 
project. 
A combinational library of R3 B1-22R analogues with mutations in position 
13 was synthesised using standard solid phase synthesis, by inserting a mixture of 
amino acids at this position.  We were able to successfully separate the more active 
analogues from the bulk of the mixture by a bioactivity guided fractionation approach. 
However, we found no mutants with especially high activity. 
 
5. Materials and methods 
 
5.1. Peptide Synthesis 
 
5.1.1. Solid phase peptide synthesis  
 
Solid phase peptide synthesis (SPPS) is a common method of synthesising 
peptides where the peptide chain is built on a solid support consisting of resin beads. 
The general principle of the synthesis is to repeat cycles with coupling of amino acids, 
and then deprotecting; removing the protecting group from the peptide chain N-
terminus to reveal a free NH2-group, ready for coupling of the next amino acid 
(Figure 24).  
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Figure 24. The basic steps in Fmoc solid phase peptide synthesis, using Rink-Amide resin. 
 
There are two major types of chemistry used in SPPS, based on the protecting 
groups on the amino acids; tert-butoxycarbonyl (Boc) and Fmoc. In these two 
methods different resins are used and the amino acids have different protection 
groups, however, the main practical difference between these methods is in the 
deprotection step and the cleavage reaction. Whereas Fmoc-chemistry uses a base 
(piperidine) to deprotect the amino acids, Boc chemistry uses an acid (typically TFA). 
When cleaving the finished peptide from the resin, a peptide synthesised using Boc-
chemistry requires hydrogen fluoride for the cleaving. With Fmoc chemistry the 
peptide can be cleaved with TFA, which is much easier and safer.  
In both types of SPPS, different chemicals can be used for the coupling 
reaction. Peptide synthesis in this project was done using O-benzotriazol-1-yl-1,1,3,3-
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tetramethyluronium hexafluorophosphate (HBTU) and diisopropylethylamine 
(DIPEA) in the coupling reactions. 
The amino acids are added to the resin together with the appropriate amount of 
HBTU and DIPEA. Synthesis on a 0.25 mmole scale uses 1 mmole of amino acid, 2 
ml of 0.5 M HBTU in N,N-dimethylformamide (DMF), and 174 µL DIPEA per 
coupling reaction. 
 
5.1.1.1. Manual synthesis 
 
The resin was placed in a reaction vessel with a sintered glass filter and a tap 
at the bottom that is connected to a vacuum line via a solvent trap. The filter allows 
reagents to be drained away while the resin, and the growing peptide, is held back in 
the vessel. 
After each coupling step a ninhydrin test was performed to get an estimate of 
the reaction yield [66]. The ninhydrin test was done by drying a small amount of resin 
and weighing out approximately 3-5 mg to a test tube. To the resin two drops of 76 % 
w/w phenol in ethanol, four drops of 0.2 M potassium cyanide in pyridine and two 
drops of 0.28 M ninhydrin in ethanol was added. The test tube was put on a heating 
block at 100 °C for five minutes together with a blank sample containing no resin. 2.8 
ml 60% ethanol in water was added, and the absorbance at 570 nm was measured 
using an ultraviolet (UV) spectrophotometer and an estimate of the yield was 
calculated using the following formula: 
 
Equation 1. Calculation of coupling percentages based on the measured absorbance from the 
ninhydrin test 
 ,  
A570 = Absorbance measured at 570 nm 
SV = Substitution value for the coupling in mmol/g 
m = mass of resin 
 
If needed, the coupling step was repeated in order to get sufficient couplings. 
The ideal coupling percentage of " 99.6 % was not always practically feasible, and in 
some cases a percentage over or close to 99 % had to suffice. 
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After an amino acid had been added, and an acceptable coupling yield had 
been achieved, the resin was washed with 3x15 ml DMF, and then treated twice with 
50/50 DMF/piperidine; first for one minute, and then three minutes. The resin was 
then thoroughly rinsed with DMF to remove all the piperidine, and was ready for 
addition of the next amino acid. 
 
5.1.1.2. Automated synthesis 
 
The automated synthesis was done on a CEM Liberty microwave synthesiser 
operated via PepDriver software. 
Double couplings were carried out on the following residues: arginine, 
isoleucine, leucine, phenylalanine, threonine, tryptophane, valine and cysteine. 
 
5.1.2. The synthesis of relaxin B-chain analogues 
 
5.1.2.1. Manual synthesis 
 
The INSL5 agonist analogue was synthesized manually using Fmoc-chemistry 
on a 0.25 mmol scale following the procedure described above (5.1.1). The resin used 
was Rink-amide MBHA (Merck), which results in an amidated C-terminus after 
peptide cleavage. 
 
5.1.2.2. Automated synthesis 
 
The synthesis of all relaxin analogues except the INSL5 agonist was done on a 
CEM Liberty microwave synthesiser using Fmoc chemistry. Synthesis of all the 
peptides except the R3 B1-22R was done on a 0.25 mmol scale. The R3 B1-22R was 
synthesised on a 0.5 mmol scale. The resin used for all these analogues was Rink-
amide MBHA (Merck). 
The synthesis of the capped relaxin analogues INSL5 antagonist, relaxin-2 




The capped relaxin analogues (see section 2.1.1) were acetylated N-terminally. 
After deprotecting the final amino acid and rinsing with DMF an acetylation mixture 
was added. The acetylation mixture was made of 15 ml DMF, 870 µL acetic 
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anhydride and 470 µL DIPEA. This mixture was split in two and the resin treated 
with the mixture for 2 x 5 minutes.  
 
5.1.3. Synthesis of the relaxin-3/chlorotoxin analogue 
 
The Relaxin-3/Chlorotoxin-analogue was synthesised on a CEM Liberty 
microwave synthesiser on a 0.25 mmoles scale using Fmoc amino acids and a Fmoc-
L-Arg(Pbf) resin (Applied biosystems). The synthesis was carried out with four times 
excess of amino acids. 
 
5.1.4. Synthesis and bioactivity guided fractionation of E13 mixture 
 
The E13-mixture was synthesized by Richard Clark on a CEM Liberty 
microwave synthesiser. A mixture of 16 amino acids (methionine, cysteine, proline 
and glycine excluded) was used in the coupling step on position 13 of the R3 B1-22R-
peptide. The amino acids in the mixture were added in different ratios according to 
their coupling efficiencies (Table 2). (Mixture composition provided by Chris 











Ala 0.95 Asn 1.2 
Asp 0.9 Gln 1.2 
Glu 0.95 Arg 1.42 
Phe 0.81 Ser 1.3 
Ile 1.16 Thr 1.6 
His 0.85 Val 1.14 
Lys 1.05 Trp 0.89 
Leu 1.08 Tyr 1.26 
 
Purification was done following a bioactivity guided fractionation approach. 
After testing, fractions eluted between 38-49 and 49-60 minutes in the HPLC on the 
original mixture seemed to have some affinity. These fractions were purified by RP-
HPLC, using a 8 ml/min column and a 0.25 % gradient. Further fractionation based 
on retention times was performed. Using ES-MS, the fractions were divided 
according to the masses each fraction contained. 
Of the final fractions, two fractions showed increased affinity compared to R3 
B1-22R, which was used as a positive control. 
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These fractions were analysed by MALDI-TOF-MS to determine which analogues the 
fractions contained. 
 
5.2. TFA cleavage 
 
All peptides except the chlorotoxin analogue were cleaved using 90 % TFA/5 
% tri-isopropylsilane (TIPS)/ 5 % distilled water. 50 ml cleaving mixture was used for 
400 mg of resin.  
The chlorotoxin analogue was cleaved from the resin using 96 ml TFA/2 ml 
TIPS/2 ml 3,6-dioxa-1,8-octanedithiol (DODT)/1 ml distilled water. 100 ml of 
cleaving mixture was used per 1 g of resin. For all peptides, the resin was left to react 
on a magnetic stirrer, in room temperature, for two hours. The resin was then filtered 
off, and TFA removed on a rotary evaporator, followed by the addition of 
approximately 100 ml cold diethyl ether to precipitate the peptide. The precipitated 
peptide was extracted with 50/50 buffer A/B using a separation funnel. Any residual 
ether was removed on the rotary evaporator and the peptide solution was lyophilised. 
 
5.3. Oxidative folding of the relaxin-3/chlorotoxin analogue 
 
Before oxidizing larger amounts of peptide, a small scale folding trial was 






1 0.1 M Tris-HCl 
0.2 M NaCl, 5 mM reduced glutathione 
0.5 mM oxidized glutathione 
7.8 
2 0.1 M NH4OAc 8.3 
3 0.1 M (NH4)2CO3 8.2 
4 0.33 M NH4OAc 
0.5 M GnHCl 
7.8 
5 0.1 M Na3PO4 7.4 
6 Buffer 1/isopropanol, 1:1  
7 Buffer 2/isopropanol, 1:1  
8 Buffer 3/isopropanol, 1:1  
9 Buffer 4/isopropanol, 1:1  
10 Buffer 5/isopropanol, 1:1  
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The samples in the folding trial were analysed by analytical HPLC after 24 
and 48 hours, and buffers 1 and 5 were subsequently used to oxidize larger amounts 
of peptide. 
Reduced, purified peptide was oxidized in buffer 1 or 5 (Table 3) to form the 
disulfide bonds. The reaction was left for 24 hours at room temperature, under 
continuous stirring. A concentration of 0.1 mg/ml peptide was used. 
1D NMR spectroscopy was used on purified peptide after folding in buffer 1 to 






The peptides were purified using RP-HPLC.  
All purification was done on one of the following systems: 
 
• Waters 600 E System Controller with a Waters 484 Tunable Absorbance Detector 
and Waters Empower software  
• Waters 600 MS System Controller with a Waters 484 Tunable Absorbance 
Detector and Delta 5.5 Chromatography Data System software 
• Shimadzu LC 20 AT Prominence Liquid Chromatograph with a Shimadzu SPD-
20A Prominence UV/VIS Detector and LC Solutions software 





o Phenomenex Jupiter C18 (250 x 21.20 mm, 300 Å pore size, 15 µm 
particle size) 
o VYDAC Protein & Peptide C18 (250 x 22 mm, 300 Å pore size, 10 µm 
particle size)  
• Semi-preparative: 
o Phenomenex C18 (250 x 10,00 5 micron, 300 Å pore size, 5 µm particle 
size) 
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o VYDAC Protein & Peptide C18 (250 x 10 mm, 300 Å pore size, 5 µm 
particle size)  
• Analytical: 
o Phenomenex Jupiter C18 (150 x 4.60 5 micron, 300 Å pore size, 5 µm 
particle size) 
 
Gradients used in purification: 
• 8 ml/min: 
o 1 % gradient of 0-80 % buffer B in 80 minutes. UV detection at 230 or 280 
nm  
o 0.5 % gradient of 0-80 % buffer B in 160 minutes. UV detection at 230 or 
280 nm  
o 0.25 % gradient of 0-80 % buffer B in 160 minutes. UV detection at 230 or 
280 nm 
• 3 ml/min: 
o 0.5 % gradient of 0-80 % buffer B in 160 minutes. UV detection at 230 or 
280 nm  
• 1 ml/min: 
o 1 % gradient of 0-80% buffer B in 80 minutes. UV detection at 215, 254 




Analytical HPLC was done on one of the following: 
• Agilent 1100 series. The column used was a Phenomenex Jupiter C18 (150 x 2.00 
mm 5 micron, 300 Å pore size, 5 µm particle size). A flow rate of 0.3 ml/min, and 
a 2 % gradient of 0-80 % buffer B in 40 minutes was used. UV-detection at 215, 
254 and 280 nm. 
• Shimadzu LC 20 AT Prominence Liquid Chromatograph with a Shimadzu SPD-
20A Prominence UV/VIS Detector and SIL-20A HT prominence autosampler, 
and LC Solutions software. The column used was a Phenomenex Jupiter C18 (150 
x 4.60 5 micron, 300 Å pore size, 5 µm particle size) or a VYDAC Protein & 







The identification of HPLC-fraction constituents was based on mass. All mass 




Identification of monoisotopic masses present in the two most active fractions 
of the E13 mixture was done on a 4700 Proteomics Analyzer MS-MS TOF-TOF from 
Applied Biosystems. 
Samples from the two fractions were made in two different dilutions by 
mixing 1 µl of the fractions re-dissolved in buffer A, with 1 or 2 µl matrix. 1 µl was 
then taken from each dilution and placed on a MALDI-plate. The sample showing the 
best signal-to-noise signal in the final spectrum was then chosen to use for mass 
determination. 
 
5.6. NMR spectroscopy 
 
0.5-1 mg purified, freeze dried sample was dissolved in distilled H2O/D2O 
(500 µL/50 µL) and subjected to solution NMR. For the experiments done at 285 K, 
4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS) was added as a reference in the 
samples. 
A 1D 1H spectrum was recorded of the relaxin-3/chlorotoxin analogue on a 
Bruker 600 MHz spectrometer. Due to the very low concentration of the sample this 
was recorded with 20000 scans to ensure a good enough signal-to-noise ratio to 
clearly observe the resonance peaks. 
2D NMR experiments included TOCSY and NOESY spectra, and were 
recorded with a mixing time of 200 ms at on a Bruker 500 MHz or a Bruker 600 MHz 
spectrometer. 
The spectra for the relaxin-3 agonist and the relaxin-2 antagonist were 
acquired at 285 K. All other spectra were acquired at 298 K. The pH in all samples 
was approximately 4. 
All spectra were analysed on Silicon Graphics Indigo Workstations using 
Topspin (Bruker) software, and analysed using CARA. 
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Spectra were assigned using the sequential assignment technique [60], and 
secondary shifts were calculated using the random coil chemical shifts described by 
Wishart et al. [61]. 
 
5.6.1. Structural calculations 
 
Structural calculations were done using CYANA software. NOE cross-peaks 
were translated into distance restraints based on peak intensities.  
The three dimensional structure was then calculated using torsion angle 
dynamics within CYANA. 20 structures were calculated, and the ten lowest energy 
structures were used to get the 3D structure of the peptide. Structures were visualised 
using the program MOLMOL [67]. 
 
5.7. Activity and binding assays 
 
All binding and activity assays were done by our collaborators at the Florey 
Neuroscience Institutes in Melbourne. 
Binding and activity assays for RXFP1 was done on HEK293T cells 
expressing the receptor, and for RXFP3 and 4 on CHO cells. 
 
5.7.1. Cyclic Adenosine Monophosphate assay 
 
CHO cells were transfected with either human RXFP3 or RXFP4 receptor, 
together with a cAMP response element (CRE)-!-galactosidase reporter plasmid as 
described by Haugaard-Kedström et al. [45]. 
After incubation, the cells were stimulated with 5 µM forskolin (RXFP3 
expressing cells) or 1 µM forskolin (RXFP4 expressing cells). Activation of RXFP3 
or 4 inhibits production of cAMP, and the activity of ligands for these receptors is 
measured by the ability to reduce the forskolin induced cAMP activity. 
The cells were stimulated with peptide, and then treated with lysis buffer and 
the ! -galactosidase substrate chlorophenol red-!-D-galactopyranoside (CPRG). The 
yellow-orange CPRG is hydrolysed by ! -galactosidase to the chromophore 
chlorophenol red and galactose, resulting in a dark red solution. The absorbance of 
chlorophenol red is proportional to cAMP production, and used as a measure of the 
activity of the receptor. The absorbance was measured at 570 nm. 
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5.7.2. Competitive binding assay 
 
Binding properties were determined by competitive binding assays on CHO 
cells stably transfected with RXFP3 or RXFP4, or HEK193T cells stably transfected 
with RXFP1. Cells were incubated with Europium(III) labelled relaxin-2, R3/I5 or 
INSL5 for assays on RXFP1, RXFP3 and RXFP4 respectively. The affinity of the 
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Figure A1. Purification and characterisation of the capped relaxin-3 analogues. 
Relaxin-3 agonist: A) ES-MS spectrum after TFA cleavage showing major masses belonging to 
the peptide. B) RP-HPLC trace of the purified peptide. C) ES-MS spectrum of purified peptide, 
confirming that the correct peptide is present. 
Relaxin-3 antagonist: D) ES-MS spectrum after TFA cleavage showing masses belonging to the 
peptide. E) RP-HPLC trace of the purified peptide. F) ES-MS spectrum of purified peptide, 





Figure A2. Purification and characterisation of the capped INSL5 analogues. 
INSL5 agonist: A) ES-MS spectrum after TFA cleavage showing masses belonging to the peptide. 
B) RP-HPLC trace of the purified peptide. C) ES-MS spectrum of purified peptide, confirming 
that the correct peptide is present. 
INSL5 antagonist: D) ES-MS spectrum after TFA cleavage showing major masses belonging to 
the peptide. E) RP-HPLC trace of the purified peptide. F) ES-MS spectrum of purified peptide, 




Figure A3. Purification and characterisation of R8A and E13A analogues of R3 B1-22R. 
R8A analogue A) ES-MS spectrum after TFA cleavage showing major masses belonging to the 
peptide. B) RP-HPLC trace of the purified peptide. C) ES-MS spectrum of purified peptide, 
confirming that the correct peptide is present. 
E13A analogue: D) ES-MS spectrum after TFA cleavage showing major masses belonging to the 
peptide. E) RP-HPLC trace of the purified peptide. F) ES-MS spectrum of purified peptide, 





Figure A4. Purification and cahracterisation of R3 B1-22R. A) ES-MS spectrum after TFA 
cleavage showing major masses belonging to the peptide. B) RP-HPLC trace of the purified 
peptide. C) ES-MS spectrum of purified peptide, confirming that the correct peptide is present. 
 
